NCT01291108

Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of AGN-210669 ophthalmic solution compared with bimatoprost ophthalmic solution (Lumigan®) as monotherapy and adjunctive therapy in patients with primary open-angle glaucoma or ocular hypertension.

Conditions

• Glaucoma, Open-Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	AGN-210669	AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
DRUG	bimatoprost	bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
DRUG	bimatoprost vehicle	bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.

Timeline

• Start date: 2011-04-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2011-02-08
• Last updated: 2013-11-06
• Results posted: 2013-11-06

Locations

1 site across 1 country: United States